Landmark Ideas Series: Dr. Julie Gerberding

Speaker: Julie Gerberding, MD, MPH, at Foundation for the National Institutes of Health, Former Director, CDC

Date: April 3, 2023 at 4:00PM - 5:30PM

Talk details will be forthcoming.

Dr. Julie Louise Gerberding is the Chief Executive Officer of the Foundation for the National Institutes of Health (FNIH).  The FNIH creates and manages research alliances with public and private institutions in support of the mission of the NIH to enhance health, lengthen life, and reduce illness and disability.  The FNIH works with its partners to accelerate biomedical research that addresses some of the most pressing health challenges in the United States and across the globe.

Formerly, Dr. Gerberding was Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she was responsible for patient engagement, strategic communications, global public policy, population health, and corporate responsibility. She joined Merck in 2010 as President of Merck Vaccines to help increase global access to important vaccines among those who need them most.

Dr. Gerberding was Director of the United States CDC from 2002-2009, where she led the agency through more than 40 emergency responses to public health crises, including SARS in 2003.  She currently co-chairs the CSIS Commission on Strengthening America’s Health Security and is a board trustee at Mayo Clinic and Case Western Reserve University and serves as a board director for HilleVax, Afternext Health Tech, and SummerBio.

Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks.  In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year.

Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University (CWRU).  She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco (UCSF) and is board certified in Internal Medicine and Infectious Diseases. She served as a tenured member of the infectious diseases faculty at UCSF and the hospital epidemiologist at San Francisco General Hospital and is currently an Adjunct Associate Professor of Medicine at UCSF and an Adjunct Professor of Medicine at CWRU.  Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley.  She is a member of the National Academy of Medicine, a member of the Council on Foreign Relations, and a fellow of the Infectious Diseases Society of America and the American College of Physicians. 


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.